Sotac Pharmaceuticals Ltd.
National Stock Exchange of IndiaTotal Valuation
Its enterprise value stands at 312.47M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | N/A |
| Enterprise Value | 312.47M |
Share Statistics
Sotac Pharmaceuticals Ltd. currently has 11.05M shares outstanding.
| Shares Outstanding | 11.05M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Enterprise Valuation
On an enterprise value basis, Sotac Pharmaceuticals Ltd. trades at an EV/EBITDA multiple of 5.89 and an EV/FCF ratio of 19.50. The EV/Sales ratio of 0.30 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 5.89 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.30 |
| EV / EBITDA | 5.89 |
| EV / EBIT | 5.89 |
| EV / FCF | 19.50 |
Financial Position
Sotac Pharmaceuticals Ltd. maintains a current ratio of 1.12, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 54.95, indicating elevated leverage, while an interest coverage ratio of 3.20 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.12 |
| Quick Ratio | 0.01 |
| Debt / Equity | 54.95 |
| Debt / EBITDA | 5.28 |
| Interest Coverage | 3.20 |
Financial Efficiency
Sotac Pharmaceuticals Ltd. posts a return on equity of 40.36 and a return on invested capital of 6.97.
| Return on Equity (ROE) | 40.36 |
| Return on Assets (ROA) | 4.16 |
| Return on Invested Capital (ROIC) | 6.97 |
| Return on Capital Employed (ROCE) | 16.04 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 4.96 |
Taxes
Over the trailing twelve months, Sotac Pharmaceuticals Ltd. has paid 1.43M in income taxes, reflecting an effective tax rate of 3.33.
| Income Tax | 1.43M |
| Effective Tax Rate | 3.33 |
Income Statement
Over the trailing twelve months, Sotac Pharmaceuticals Ltd. generated 1.05B in revenue and converted that into 44.60M in net income, yielding earnings per share of 3.77. EBITDA reached 53.05M, while operating income came in at 53.05M.
| Revenue | 1.05B |
| Gross Profit | 217.38M |
| Operating Income | 53.05M |
| Pretax Income | 42.95M |
| Net Income | 44.60M |
| EBITDA | 53.05M |
| EBIT | 53.05M |
| Earnings Per Share (EPS) | 3.77 |
Balance Sheet
Sotac Pharmaceuticals Ltd. holds 5.21M in cash and equivalents against 279.88M in total debt, resulting in a net debt position of 274.66M. Total book value stands at 110.50M, with working capital of 65.21M providing operational flexibility.
| Cash & Cash Equivalents | 5.21M |
| Total Debt | 279.88M |
| Net Debt | 274.66M |
| Equity (Book Value) | 110.50M |
| Book Value Per Share | 10.03 |
| Working Capital | 65.21M |
Margins
Sotac Pharmaceuticals Ltd. operates with a gross margin of 20.75, reflecting its pricing power and cost economics. The operating margin of 5.06 and net profit margin of 4.26 provide insight into operational efficiency.
| Gross Margin | 20.75 |
| Operating Margin | 5.06 |
| Pretax Margin | 4.10 |
| Profit Margin | 4.26 |
| EBITDA Margin | 5.06 |
Scores
Sotac Pharmaceuticals Ltd. posts an Altman Z-Score of 1.15, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.15 |